Copyright © 2021. Inderes Oyj. All rights reserved.

Genovis AB

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
12.8.
2021
Second quarter 2021    
  • Net sales rose by 26% to SEK 19,535 (15,490) thousand. Growth is 37%, adjusted for currency effects.
  • Gross profit rose by 32% to SEK 17,365 (13,146) thousand.
  • Operating profit before depreciation and amortization (EBITDA) totaled SEK 2,793 (loss: 38) thousand.
  • Operating profit improved by SEK 2,641 thousand and totaled SEK 1,350 (loss: 1,291) thousand.
  • Comprehensive income for the period improved by SEK 4,156 thousand and totaled SEK 1,033 (loss: 3,123) thousand.
  • Comprehensive income per share, basic and diluted,
Tiedotteet
7.6.
2021

Under the agreements, the combined proprietary technology platform will enable Genovis and GlycoT Therapeutics ("GlycoT") to market, sell and further develop enzymatic workflows for the research and diagnostics markets as well as for therapeutic applications.

Tiedotteet
20.5.
2021

The Annual General Meeting adopted the following resolutions:

  • The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.

  • The Board and the Chief Executive Officer were discharged from liability.

  • The Board shall consist until the next AGM of five ordinary members without deputies.

  • Re-election of Board membersTorben Jørgensen,Mikael Lönn, Kenth Petersson and Lotta Ljungqvist.

Steve Jordanwas elected new Board member.

Tiedotteet
29.4.
2021

First quarter in brief

  •                     Net sales rose by 37 percent to SEK 15,723 (11,475) thousand. Organic growth was 21%.

  •                     Gross profit was SEK 15,017 (10,977) thousand.

  •                     Operating profit before depreciation and amortization (EBITDA) totaled SEK 1,958 (loss: 847) thousand.

  •                     Operating profit totaled SEK 551 (loss: 1,889) thousand.

  •                     Comprehensive income for the period totaled SEK 1,607 (loss: 1,915) thousand.

Tiedotteet
28.4.
2021

Genovis 2020 Annual Report is now available in Swedish and English at our website.

To read or download the annual report in Swedish, go to:

https://investor.genovis.com/wp-content/uploads/genovis-arsredovisning-2020.pdf

To read or download the annual report in English, go to:

https://investor.genovis.com/wp-content/uploads/genovis-annual-report-2020.pdf

Tiedotteet
14.4.
2021

The shareholders of Genovis AB, corporate identity no 556574-5345, are hereby given notice of the Annual General Meeting on Thursday, May 20, 2021.

Tiedotteet
13.4.
2021
Firms Working to Co-Develop Automated Biotherapeutic Characterization Workflows, Combining Genovis SmartEnzymes™ and Waters LC-MS Instrumentation.
  • Collaboration intended to bring speed and simplicity to bio-characterization workflows

  • Automated workflows to cut the time and effort required to monitor critical quality attributes of biotherapeutics in regulated laboratories

  • Waters and Genovis share mutual goal to advance the science behind the analysis of glycoproteins and protein therapeutics

Tiedotteet
29.3.
2021

Genovis AB's (publ) Chief Financial Officer (CFO) Johny Humaloja has resigned from his position to take on new challenges.

Johny has been employed by Genovis since 2019 and he will continue in his current role during the notice period. A process to recruit a new CFO will be initiated immediately.

"During his time at Genovis, Johny has contributed to the development of the Group's financial management. I would like to thank him for his contribution to Genovis and wish him good luck in his new endeavors," says Fredrik Olsson, CEO of Genovis

Tiedotteet
2.3.
2021

The Nomination Committee proposes that Genovis should expand its Board of Directors at the 2021 Annual General Meeting and proposes Steve Jordan to be elected as a new board member.

Tiedotteet
11.2.
2021

Report for the fourth quarter of 2020          

Genovis AB